Regulatory approval

Published by the Health Canada. Approved

SCEMBLIX (asciminib tablets) is indicated for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received one or more tyrosine kinase inhibitors.

This is written in the approval document.

Citation

Novartis Pharmaceuticals Canada Inc. Scemblix (asciminib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00081936.PDF. Revised October 2025. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
HC (1)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib